Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
AEZS
$2.71
Aeterna Zentaris
($.04)
(1.45%)
AEZS
Earnings Whisper ®
N/A
4th Quarter December 2022
Consensus: ($0.93)
Revenue: $1.06 Mil
Monday
Mar 27
8:05 AM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
Thursday, November 3, 2022
Aeterna Zentaris Reports Third Quarter 2022 Financial Results
What do you expect when AEZS reports earnings?
Beat
Meet
Miss
Where is AEZS's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
-
-
-
-
Support
-
-
-
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers.
Peers
Regeneron Pharmaceuticals
BioMarin Pharmaceutical
Bristol-Myers Squibb
Johnson & Johnson
Eli Lilly
Vertex Pharmaceuticals
Merck & Co.
Pfizer
Array Technologies
Ultragenyx Pharmaceutical
Expectations
›
Aeterna Zentaris